Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plitidepsin in Immunocompromised COVID-19 Patients
NCT05705167Phase 2Terminated
- Sponsor
- PharmaMar
- Start
- Apr 2023
- Primary completion
- Mar 2024
- Modality
- Cyclic Peptides, Peptide-Drug Conjugates
- Countries
- 11
01
Overview
A Phase 2 trial of plitidepsin in coronavirus disease 2019 (COVID-19), sponsored by PharmaMar. Started Apr 2023; status: terminated.
02
Drugs
plitidepsin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05705167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05705167.